Venlafaxine versus placebo in the preventive treatment of recurrent major depression.

@article{Montgomery2004VenlafaxineVP,
  title={Venlafaxine versus placebo in the preventive treatment of recurrent major depression.},
  author={Stuart A. Montgomery and Richard Entsuah and David Hackett and Nadia R Kunz and Richard L. Rudolph},
  journal={The Journal of clinical psychiatry},
  year={2004},
  volume={65 3},
  pages={328-36}
}
BACKGROUND Major depression is often chronic and recurrent, yet most long-term therapeutic trials are not adequately designed to assess antidepressant efficacy in recurrence prevention. Long-term efficacy and safety of prophylactic venlafaxine treatment were evaluated in outpatients with recurrent major depression. METHOD Patients with a history of recurrent DSM-III-R major depression received open-label treatment with venlafaxine, 100 to 200 mg/day, for 6 months. Those who responded to… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Remission from depression

PharmacoEconomics • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…